SOURCE: Edwards Lifesciences

Edwards Lifesciences

September 13, 2011 14:37 ET

Edwards Lifesciences' Board of Directors Approves New $500 Million Share Repurchase Program

IRVINE, CA--(Marketwire - Sep 13, 2011) - Edwards Lifesciences Corporation (NYSE: EW), the global leader in the science of heart valves and hemodynamic monitoring, announced today that its board of directors has authorized a new share repurchase program to acquire up to an additional $500 million of the company's outstanding common shares. As of June 30, 2011, Edwards had approximately $240 million remaining of its current $500 million share repurchase program, which was authorized in February 2010. Edwards expects to purchase approximately $100 million of additional shares during the third quarter of 2011.

"We are confident in the long-term outlook of the company and believe this new stock repurchase program gives us an opportunity to continue to return value to our stockholders," said Michael A. Mussallem, Edwards Lifesciences' chairman and CEO.

The company may repurchase shares in the open market or in privately negotiated transactions. The timing and extent of any repurchase will depend upon market conditions, corporate requirements and other factors.

About Edwards Lifesciences
Edwards Lifesciences is the global leader in the science of heart valves and hemodynamic monitoring. Driven by a passion to help patients, the company partners with clinicians to develop innovative technologies in the areas of structural heart disease and critical care monitoring that enable them to save and enhance lives. Additional company information can be found at

This news release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements include, but are not limited to, Mr. Mussallem's statement and estimates for the timing, manner and magnitude of share repurchases. Forward-looking statements are based on estimates and assumptions made by management of the company and are believed to be reasonable, though they are inherently uncertain and difficult to predict. Our forward-looking statements speak only as of the date on which they are made and we do not undertake any obligation to update any forward-looking statement to reflect events or circumstances after the date of the statement. Forward-looking statements involve risks and uncertainties that could cause actual results or experience to differ materially from those expressed or implied by the forward-looking statements based on a number of factors including but not limited to unexpected market developments for the company's products, new approvals, clinical trials or reimbursement, economic conditions impacting healthcare, and general stock market conditions. These and other factors are detailed in the company's filings with the Securities and Exchange Commission including its Annual Report on Form 10-K for the year ended December 31, 2010.

Edwards, Edwards Lifesciences and the stylized E logo are trademarks of Edwards Lifesciences Corporation.

Contact Information

  • Media Contact:
    Amanda C. Fowler
    Investor Contact:
    David K. Erickson

    Edwards Lifesciences Corporation
    One Edwards Way
    Irvine, CA USA 92614
    Phone: 949.250.2500
    Fax: 949.250.2525